Leede Financial Has Positive View of TSE:ONC FY2025 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Leede Financial boosted their FY2025 earnings estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings per share of ($0.40) for the year, up from their previous forecast of ($0.41). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Trading Up 1.1 %

Shares of Oncolytics Biotech stock opened at C$0.91 on Thursday. The company’s fifty day simple moving average is C$1.10 and its 200-day simple moving average is C$1.30. The stock has a market capitalization of C$70.14 million, a PE ratio of -2.54 and a beta of 1.35. Oncolytics Biotech has a 1-year low of C$0.86 and a 1-year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.